Chun Khai Chong, MD
Nephrology · Portland, ORNPI 1932367117
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $712 of the $956 with a category attached, or 74.4%. It is spread thinly across 15 manufacturers, the largest accounting for just 20.9%. 2025 is the largest year on record at $358, more than ten times the $4 reported in 2019.
Across 39 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$200
- Otsuka America Pharmaceutical, Inc.$117
- Calliditas Therapeutics US Inc.$116
- Ardelyx, Inc.$102
- Amgen$83
- AstraZeneca$74
- plus $264 from 9 others
What the payments were for
- Speaking & faculty fees$20021%
- Travel & lodging$91%
- Food & beverage$71274%
- Education$354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 1 | $200 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Calliditas Therapeutics US Inc. | 5 | $116 |
| Ardelyx, Inc. | 1 | $102 |
| Amgen(2 entities) | 4 | $83 |
| AstraZeneca | 5 | $74 |
| Travere Therapeutics, Inc. | 8 | $66 |
| Novartis | 2 | $43 |
| Bayer | 2 | $34 |
| Akebia Therapeutics Inc | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
- XPHOZAH 30 MG$102
How this compares
$956 in reported general payments places this provider in the 80th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 189 | $147,310 |
| VeltassaPatiromer Calcium Sorbitex | 33 | $35,972 |
| DapagliflozinDapagliflozin Propanediol | 51 | $33,815 |
| Lanthanum Carbonate | 24 | $28,770 |
| JardianceEmpagliflozin | 40 | $24,333 |
| Sevelamer Carbonate | 86 | $14,233 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,318 |
| Potassium Citrate ErPotassium Citrate | 38 | $4,962 |
| Febuxostat | 29 | $1,734 |
| Nifedipine ErNifedipine | 37 | $1,492 |
| Losartan Potassium | 110 | $1,269 |
| Hydralazine Hcl | 60 | $1,259 |
| Torsemide | 55 | $1,195 |
| Calcium Acetate | 16 | $1,087 |
| Calcitriol | 104 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $74 | $155,628201 claims |
| Boehringer IngelheimJardiance | $23 | $24,33340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 nephrology providers in Oregon.
Other nephrology in Portland
- Robert ProvenzanoPortland$45K
- Nayan AroraPortland$23K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
- Shehzad RehmanPortland$10K
- Arthur GreenbergPortland$7K
- Suzanne WatnickPortland$2K
- Hem DeodharPortland$1K
- Julia TankPortland$1K
- Maria Theresa de JesusPortland$857
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.